{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:35:06Z","timestamp":1790184906814,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-22-PEBI-0009"],"award-info":[{"award-number":["ANR-22-PEBI-0009"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejpb.2026.114990","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:04:15Z","timestamp":1768705455000},"page":"114990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The THP-1 cell line as a model for the assessment of monoclonal antibodies aggregates\u2019 immunological effects"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0832-6721","authenticated-orcid":false,"given":"Maria","family":"Lteif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abratanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Turbica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pallardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejpb.2026.114990_b0190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/abt\/tbac021","article-title":"The global landscape of approved antibody therapies","volume":"5","author":"Lyu","year":"2022","journal-title":"Antibody Therapeutics"},{"key":"10.1016\/j.ejpb.2026.114990_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.885672","article-title":"Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients","volume":"13","author":"Mosch","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2026.114990_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/604872","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with TNF \u03b1 blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"2015","author":"Arstikyte","year":"2015","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ejpb.2026.114990_b0250","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Therapeutic Advances in Chronic Disease"},{"key":"10.1016\/j.ejpb.2026.114990_b0125","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation\u2013updated consensus and review 2020","volume":"11","author":"Jawa","year":"2020","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.ejpb.2026.114990_b0305","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.4155\/bio-2018-0246","article-title":"Nonclinical immunogenicity risk assessment of therapeutic proteins","volume":"11","author":"Tourdot","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ejpb.2026.114990_b0315","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0120","doi-asserted-by":"crossref","first-page":"11332","DOI":"10.1038\/s41598-021-90772-9","article-title":"Freeze\u2013thaw characterization process to minimize aggregation and enable drug product manufacturing of protein based therapeutics","volume":"11","author":"Jain","year":"2021","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2026.114990_b0335","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2018.08.043","article-title":"Protein aggregation \u2013 Mechanisms, detection, and control","volume":"550","author":"Wang","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2026.114990_b0005","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s11095-014-1541-x","article-title":"Small Amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics","volume":"32","author":"Ahmadi","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.114990_b0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fimmu.2019.00601","article-title":"Evaluation of in vitro assays to assess the modulation of dendritic cells functions by therapeutic antibodies and aggregates","volume":"10","author":"Morgan","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086322","article-title":"Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro","volume":"9","author":"Rombach-Riegraf","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","article-title":"THP-1 cell line: an in vitro cell model for immune modulation approach","volume":"23","author":"Chanput","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2026.114990_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2022.814050","article-title":"The modified THP-1 activation assay for the in vitro identification of drug-inducing systemic hypersensitivity","volume":"4","author":"Iulini","year":"2022","journal-title":"Front. Toxicol."},{"issue":"30","key":"10.1016\/j.ejpb.2026.114990_b0135","doi-asserted-by":"crossref","first-page":"25266","DOI":"10.1074\/jbc.M111.330902","article-title":"Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses","volume":"287","author":"Joubert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2026.114990_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.915412","article-title":"Immunogenicity risk assessment of spontaneously occurring therapeutic monoclonal antibody aggregates","volume":"13","author":"Swanson","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2026.114990_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113147","article-title":"Comparability study of monocyte derived dendritic cells, primary monocytes, and THP1 cells for innate immune responses","volume":"498","author":"Wen","year":"2021","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/1547691X.2020.1727071","article-title":"Immunostimulatory effects on THP-1 cells by peptide or protein pharmaceuticals associated with injection site reactions","volume":"17","author":"Hamamura-Yasuno","year":"2020","journal-title":"J. Immunotoxicol."},{"issue":"8","key":"10.1016\/j.ejpb.2026.114990_b0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043361","article-title":"Fc Gamma receptor CD64 modulates the inhibitory activity of infliximab","volume":"7","author":"Wojtal","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ejpb.2026.114990_b0225","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s11095-016-1914-4","article-title":"Physical characterization and innate immunogenicity of aggregated intravenous immunoglobulin (IGIV) in an in vitro cell-based model","volume":"33","author":"Moussa","year":"2016","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.ejpb.2026.114990_b0155","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.ejpb.2026.114990_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179308","volume":"12","author":"Moots","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2026.114990_b0310","doi-asserted-by":"crossref","unstructured":"Ungar, B., Chowers, Y., Yavzori, M., Picard, O., Fudim, E., Har-Noy, O., Kopylov, U., Eliakim, R., Ben-Horin, S., & on behalf of ABIRISK consortium, 2014. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut, 63(8), 1258\u20131264. Doi: 10.1136\/gutjnl-2013-305259.","DOI":"10.1136\/gutjnl-2013-305259"},{"issue":"5","key":"10.1016\/j.ejpb.2026.114990_b0320","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/gutjnl-2016-313071","article-title":"Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial","volume":"67","author":"Van Stappen","year":"2018","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.ejpb.2026.114990_b0235","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.4049\/jimmunol.1901381","article-title":"The Fc\u03b3RIIa\u2013Syk axis controls human dendritic cell activation and T cell response induced by infliximab aggregates","volume":"205","author":"Nabhan","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2026.114990_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106670","article-title":"Infliximab aggregates produced in severe and mild elevated temperature stress conditions induce an extended specific CD4 T-cell response","volume":"192","author":"Nabhan","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.114990_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00070","article-title":"The dendritic cell synapse: a life dedicated to T cell activation","volume":"7","author":"Benvenuti","year":"2016","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1958590","article-title":"Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding","volume":"10","author":"Jin","year":"2021","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.ejpb.2026.114990_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250340","article-title":"Antibodies internalization mechanisms by dendritic cells and their role in therapeutic antibody immunogenicity","volume":"54","author":"Lteif","year":"2024","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.ejpb.2026.114990_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040999","article-title":"PKC-dependent human monocyte adhesion requires AMPK and Syk activation","volume":"7","author":"Chang","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejpb.2026.114990_b0175","doi-asserted-by":"crossref","first-page":"a002352","DOI":"10.1101\/cshperspect.a002352","article-title":"Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk","volume":"3","author":"Lowell","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6","key":"10.1016\/j.ejpb.2026.114990_b0205","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.ejpb.2026.114990_b0035","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.cellsig.2010.03.001","article-title":"The Src, Syk, and Tec family kinases: distinct types of molecular switches","volume":"22","author":"Bradshaw","year":"2010","journal-title":"Cell. Signal."},{"issue":"10","key":"10.1016\/j.ejpb.2026.114990_b0140","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.4049\/jimmunol.161.10.5276","article-title":"Syk- and lyn-dependent phosphorylation of Syk on multiple tyrosines following B cell activation includes a site that negatively regulates signaling","volume":"161","author":"Keshvara","year":"1998","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12989-023-00527-9","article-title":"Human dendritic cell maturation induced by amorphous silica nanoparticles is Syk-dependent and triggered by lipid raft aggregation","volume":"20","author":"Guillet","year":"2023","journal-title":"Part. Fibre Toxicol."},{"issue":"10","key":"10.1016\/j.ejpb.2026.114990_b0260","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1016\/j.molimm.2008.01.011","article-title":"The tyrosine kinase Syk promotes phagocytosis of Francisella through the activation of Erk","volume":"45","author":"Parsa","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejpb.2026.114990_b0295","doi-asserted-by":"crossref","unstructured":"Slack, E. C., Robinson, M. J., Hernanz\u2010Falc\u00f3n, P., Brown, G. D., Williams, D. L., Schweighoffer, E., Tybulewicz, V. L., & Reise Sousa, C., 2007. Syk\u2010dependent ERK activation regulates IL\u20102 and IL\u201010 production by DC stimulated with zymosan. Eur. J. Immunol. 37(6), 1600\u20131612. Doi: 10.1002\/eji.200636830.","DOI":"10.1002\/eji.200636830"},{"issue":"5","key":"10.1016\/j.ejpb.2026.114990_b0055","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.ejpb.2026.114990_b0265","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/19420862.2017.1347741","article-title":"Biosimilarity under stress: a forced degradation study of Remicade\u00ae and RemsimaTM","volume":"9","author":"Pisupati","year":"2017","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.ejpb.2026.114990_b0255","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.xphs.2016.09.028","article-title":"Microparticles and nanoparticles delivered in intravenous saline and in an intravenous solution of a therapeutic antibody product","volume":"106","author":"Pardeshi","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.114990_b0285","doi-asserted-by":"crossref","unstructured":"S\u00e9cher, T., Bodier-Montagutelli, E., Parent, C., Bouvart, L., Cortes, M., Ferreira, M., MacLoughlin, R., Ilango, G., Schmid, O., Respaud, R., Heuz\u00e9-Vourc\u2019h, N., 2022. Aggregates Associated with Instability of Antibodies during Aerosolization Induce Adverse Immunological Effects. Pharmaceutics, 14(3), 671. Doi: 10.3390\/pharmaceutics14030671.","DOI":"10.3390\/pharmaceutics14030671"},{"issue":"4","key":"10.1016\/j.ejpb.2026.114990_bib351","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.xphs.2022.12.027","article-title":"Impact of Stress on the Immunogenic Potential of Adalimumab","volume":"112","author":"Heljo","year":"2023","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"5","key":"10.1016\/j.ejpb.2026.114990_b0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.tiv.2005.10.012","article-title":"Development of an in vitro skin sensitization test using human cell lines: the human cell line activation test (h-CLAT)","volume":"20","author":"Ashikaga","year":"2006","journal-title":"Toxicol. In Vitro"},{"issue":"2","key":"10.1016\/j.ejpb.2026.114990_b0110","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3390\/ijms24021452","article-title":"The monocytic cell line THP-1 as a validated and robust surrogate model for human dendritic cells","volume":"24","author":"H\u00f6lken","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2026.114990_b0105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/toxsci\/kfr174","article-title":"Cross talk between keratinocytes and dendritic cells: impact on the prediction of sensitization","volume":"123","author":"Hennen","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2026.114990_b0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/icb.2016.100","article-title":"Effect of growth hormone and IgG aggregates on dendritic cells activation and T\u2010cells polarization","volume":"95","author":"Gallais","year":"2017","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0040","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190314","article-title":"Inflammasome signaling and regulation of interleukin-1 family cytokines","volume":"217","author":"Chan","year":"2020","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.ejpb.2026.114990_b0020","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.4049\/jimmunol.170.8.3963","article-title":"Cross-linking of CD32 induces maturation of human monocyte-derived dendritic cells via NF-\u03baB signaling pathway","volume":"170","author":"B\u00e1nki","year":"2003","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0165","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.ejpb.2026.114990_b0195","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1074\/jbc.M410994200","article-title":"Interleukin-8 Induces Nuclear Transcription factor-\u03baB through a TRAF6-dependent Pathway","volume":"280","author":"Manna","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2026.114990_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2021.04.002","article-title":"Inflammasomes in dendritic cells: friend or foe?","volume":"234","author":"Hatscher","year":"2021","journal-title":"Immunol. Lett."},{"issue":"5","key":"10.1016\/j.ejpb.2026.114990_b0080","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.intimp.2008.01.013","article-title":"Effects of three anti-TNF-\u03b1 drugs: Etanercept, infliximab and pirfenidone on release of TNF-\u03b1 in medium and TNF-\u03b1 associated with the cell in vitro","volume":"8","author":"Grattendick","year":"2008","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2026.114990_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104146","article-title":"THP-1 cells increase TNF-\u03b1 production upon LPS + soluble human IgG co-stimulation supporting evidence for TLR4 and Fc\u03b3 receptors crosstalk","volume":"355","author":"Vargas-Hern\u00e1ndez","year":"2020","journal-title":"Cell. Immunol."},{"issue":"10","key":"10.1016\/j.ejpb.2026.114990_b0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0245","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2026.114990_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188497","article-title":"Fc receptors act as innate immune receptors during infection?","volume":"14","author":"Laassili","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2026.114990_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2015.00001","article-title":"Macropinocytosis in phagocytes: Regulation of MHC class-II-restricted antigen presentation in dendritic cells","volume":"6","author":"Liu","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejpb.2026.114990_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1617395","article-title":"Antigen-presenting cell internalization is key for understanding and evaluating therapeutic antibodies\u2019 immunogenicity","volume":"16","author":"Lteif","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2026.114990_b0075","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.talanta.2017.09.083","article-title":"Monoclonal antibody N-glycosylation profiling using capillary electrophoresis \u2013 Mass spectrometry: assessment and method validation","volume":"178","author":"Giorgetti","year":"2018","journal-title":"Talanta"},{"key":"10.1016\/j.ejpb.2026.114990_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.ejpb.2026.114990_b0095","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.3390\/ijms23169038","article-title":"Membrane internalization mechanisms and design strategies of arginine-rich cell-penetrating peptides","volume":"23","author":"Hao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2026.114990_b0200","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.apsb.2021.02.019","article-title":"Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers","volume":"11","author":"Mazumdar","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.ejpb.2026.114990_b0275","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2026.114990_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666813","article-title":"Fc Binding by Fc\u03b3RIIa is essential for cellular activation by the anti-Fc\u03b3RIIa mAbs 8.26 and 8.2","volume":"12","author":"Wines","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0230","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.xphs.2019.09.007","article-title":"Growth hormone aggregates activation of human dendritic cells is controlled by Rac1 and PI3 kinase signaling pathways","volume":"109","author":"Nabhan","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0270","doi-asserted-by":"crossref","first-page":"11477","DOI":"10.1038\/s41598-018-29850-4","article-title":"Aggregates of IVIG or Avastin, but not HSA, modify the response to model innate immune response modulating impurities","volume":"8","author":"Polumuri","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2026.114990_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.815020","article-title":"Role of Lipid Rafts In Pathogen-Host Interaction\u2014A Mini Review","volume":"12","author":"Kulkarni","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.114990_b0330","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imm.12617","article-title":"Lipid rafts in immune signalling: current progress and future perspective","volume":"149","author":"Varshney","year":"2016","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.ejpb.2026.114990_b0160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14728222.2014.877891","article-title":"Targeting the Fc receptor in autoimmune disease","volume":"18","author":"Li","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.ejpb.2026.114990_b0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nm.2306","article-title":"Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity","volume":"17","author":"Flach","year":"2011","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.ejpb.2026.114990_b0290","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4049\/jimmunol.170.2.846","article-title":"A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation","volume":"170","author":"Sedlik","year":"2003","journal-title":"J. Immunol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:35:06Z","timestamp":1770284106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":71,"alternative-id":["S0939641126000111"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.114990","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The THP-1 cell line as a model for the assessment of monoclonal antibodies aggregates\u2019 immunological effects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.114990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114990"}}